Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
Status:
Terminated
Trial end date:
2005-01-10
Target enrollment:
Participant gender:
Summary
This Phase II study is designed to determine whether a single 600 mg dose or 400mg/day for 3
days of tafenoquine is efficacious, and well tolerated for clearing P. vivax malaria
infection (blood schizontocidal and gametocytocidal activity) and preventing P. vivax relapse
(hypnozoite eradication). It will also further establish the safety and tolerability of these
doses of tafenoquine.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command